Literature DB >> 186411

Synergistic effect on mortality in mice with murine cytomegalovirus and Pseudomonas aeruginosa, Staphylococcus aureus, or Candida albicans infections.

J R Hamilton, J C Overall, L A Glasgow.   

Abstract

A synergistic effect on mortality was demonstrated in a combined infection of mice with murine cytomegalovirus (MCMV) and Pseudomonas aeruginosa, Staphylococcus aureus, or Candida albicans. Mice infected intraperitoneally with a 0 to 20% lethal dose inoculum of MCMV 3 days prior to the intravenous injection of a 0 to 20% lethal dose inoculum of either the bacteria or fungus demonstrated a striking enhancement of mortality. MCMV-infected mice given Pseudomonas or Staphylococcus exhibited a 90 to 100% mortality within 24 to 48 h, whereas 80% of viral-infected animals injected with Candida died in 5 days. Injection of the bacteria or fungus at various times during the MCMV infection resulted in enhanced mortality on days 0,1,2, and 3 of the viral infection. Greatest synergism was observed on day 3, with a progressive decline in death rates thereafter. Immunization with MCMV abrogated the synergistic effect on mortality in all three combined infections. Immunization with Pseudomonas reduced mortality in the combined MCMV-Pseudomonas infection. These results indicate that mice exhibit a markedly enhanced susceptibility to bacterial and fungal infections during the course of the MCMV infection and suggest that the enhancement may be related to viral-induced alterations in host resistance.

Entities:  

Mesh:

Year:  1976        PMID: 186411      PMCID: PMC415482          DOI: 10.1128/iai.14.4.982-989.1976

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  37 in total

1.  Synergistic effect in viral-bacterial infection. I. Combined infection of the respiratory tract in mice with parainfluenza virus and Hemophilus influenza.

Authors:  M Degré; L A Glasgow
Journal:  J Infect Dis       Date:  1968-12       Impact factor: 5.226

2.  Cytomegalovirus infection after renal transplantation. Report of a case with viremia and atypical lymphocytosis.

Authors:  S L Balakrishnan; D Armstrong; A L Rubin; K H Stenzel
Journal:  JAMA       Date:  1969-03-03       Impact factor: 56.272

Review 3.  Virus infections of the fetus and newborn infant.

Authors:  J C Overall; L A Glasgow
Journal:  J Pediatr       Date:  1970-08       Impact factor: 4.406

4.  The role of polymorphonuclear leucocytes in protecting mice vaccinated against Pseudomon as aeruginosa infections.

Authors:  R J Jones; R E Dyster
Journal:  Br J Exp Pathol       Date:  1973-08

5.  Immunosuppression during acute murine cytomegalovirus infection.

Authors:  J E Osborn; A A Blazkovec; D L Walker
Journal:  J Immunol       Date:  1968-04       Impact factor: 5.422

6.  Cytomegalovirus infection. Viral ultrastructure with particular reference to the relationship of lysosomes to cytoplasmic inclusions.

Authors:  B H Ruebner; T Hirano; R Slusser; J Osborn; D N Medearis
Journal:  Am J Pathol       Date:  1966-06       Impact factor: 4.307

7.  Cytomegalovirus as a possible cause of a disease resembling infectious mononucleosis.

Authors:  E Klemola; L Kääriäinen
Journal:  Br Med J       Date:  1965-11-06

8.  Suppression of interferon and antibody and multiplication of Newcastle disease virus in cytomegalovirus infected mice.

Authors:  J E Osborn; D N Medearis
Journal:  Proc Soc Exp Biol Med       Date:  1967-02

9.  Enhancement of bacterial infections in mice by newcastle disease virus.

Authors:  R Hugh; K Y Huang; T B Elliott
Journal:  Infect Immun       Date:  1971-03       Impact factor: 3.441

10.  Role of macrophages in resistance to murine cytomegalovirus.

Authors:  M K Selgrade; J E Osborn
Journal:  Infect Immun       Date:  1974-12       Impact factor: 3.441

View more
  30 in total

1.  Characterization of a murine cytomegalovirus-induced immunosuppressive factor.

Authors:  P F Whyte; R Subramaniam; J B Hudson
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

Review 2.  The murine cytomegalovirus as a model for the study of viral pathogenesis and persistent infections.

Authors:  J B Hudson
Journal:  Arch Virol       Date:  1979       Impact factor: 2.574

3.  Proliferative and interferon responses by peripheral blood mononuclear cells after bone marrow transplantation in humans.

Authors:  M J Levin; R Parkman; M N Oxman; J M Rappeport; M Simpson; P L Leary
Journal:  Infect Immun       Date:  1978-06       Impact factor: 3.441

4.  Acute cytomegalovirus infection and the host immune response. II. Relationship of suppressed in vitro lymphocyte reactivity to bacterial recall antigens and mitogens with the development of cytomegalovirus-induced lymphocyte reactivity.

Authors:  C H ten Napel; T H The
Journal:  Clin Exp Immunol       Date:  1980-02       Impact factor: 4.330

5.  Comparison of serological tests for the detection of antibody to natural and experimental murine cytomegalovirus.

Authors:  G Lussier; D Guénette; J P Descôteaux
Journal:  Can J Vet Res       Date:  1987-04       Impact factor: 1.310

Review 6.  Mechanisms of virus-induced immune suppression.

Authors:  M A Wainberg; E L Mills
Journal:  Can Med Assoc J       Date:  1985-06-01       Impact factor: 8.262

7.  Peritoneal macrophage activation indicated by enhanced chemiluminescence.

Authors:  C J Schleupner; L A Glasgow
Journal:  Infect Immun       Date:  1978-09       Impact factor: 3.441

Review 8.  Herpesvirus-bacteria synergistic interaction in periodontitis.

Authors:  Casey Chen; Pinghui Feng; Jørgen Slots
Journal:  Periodontol 2000       Date:  2020-02       Impact factor: 7.589

Review 9.  A review of infectious bovine rhinotracheitis, shipping fever pneumonia and viral-bacterial synergism in respiratory disease of cattle.

Authors:  W D Yates
Journal:  Can J Comp Med       Date:  1982-07

10.  Histopathological changes in the lungs of influenza-infected mice superinfected with Staphylococcus aureus.

Authors:  I D Gardner; T M Kung
Journal:  Br J Exp Pathol       Date:  1980-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.